Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723021 · ClinicalTrials.gov registry record · Phase 2
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
A Phase 2 study of Asthma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT00723021 is a Phase 2 study of Asthma that has completed, run by Pfizer. The registered enrollment target is 15 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00723021, a Phase 2 study of Asthma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
Conditions Studied
Interventions
- DRUG Placebo
- DRUG zileuton
- DRUG PF-04191834
Study Locations (4)
Maryland
- Pfizer Investigational Site - Baltimore
Massachusetts
- Pfizer Investigational Site - North Dartmouth
Michigan
- Pfizer Investigational Site - Kalamazoo
Nebraska
- Pfizer Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723021
The ClinicalTrials.gov registry entry for NCT00723021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00723021 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT00723021 about?
NCT00723021 is a clinical study titled "PF-04191834 Single Dose Bronchodilatory Study In Asthma.". Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
What is the current status of trial NCT00723021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00723021 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00723021?
The interventions under investigation include: Placebo (DRUG), zileuton (DRUG), PF-04191834 (DRUG).
Who is sponsoring clinical trial NCT00723021?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723021 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.